
primary studies - published RCT

Hypertonic saline and recombinant human DNase: a randomised cross-over pilot study in patients with cystic fibrosis.

Code: PM15463808

Year: 2002 **Date:** 2002

Author: Ballmann M

Study design (if review, criteria of inclusion for studies)

Open cross-over pilot trial, with 2 treatment periods of 3 weeks, with a 3-week washout period.

Participants

Withdrawals were not discussed within the paper. 14 participants (mean age 13.3 years) with mild to moderate pulmonary involvement.

Interventions

Treatment consisted of 2 puffs salbutamol via a spacer prior to nebulization of 10 ml HS or 2.5 mg dornase alfa od.

Outcome measures

Changes from baseline for FEV1 (% predicted). Participants were assessed before and after each period.

<http://www.journals.elsevier.com/journal-of-cystic-fibrosis/>

See also

J Cyst Fibros. 2002 Mar;1(1):35-7.

Keywords

Adolescent; Child; Deoxyribonuclease; Airway clearance drugs -expectorants- mucolytic- mucociliary-; hydration; Hypertonic Solutions; Inhalation OR nebulised; pharmacological_intervention; Recombinant Proteins; Respiratory System Agents; Respiratory Tract Diseases; Dornase alpha; Pulmozyme;